Relationship between FOLFOX Chemotherapy of Colorectal Cancer Patients and GSTP1,XRCC1 Gene Polymorphism / 现代检验医学杂志

ABSTRACT

Objective To explore the relationship between FOLFOX Chemotherapy and GSTP1,XRCC1 gene polymorphism in patients with colorectal cancer.Methods 60 cases of colorectal cancer treated in Tumor hospital of Hunan Province from January to December 2014 were selected as the research object.Treat patients with modified FOLFOX regimen,determined the GSTP1 ,XRCC1 gene sequence polymorphism,and explored the relationship between the efficacy and the GSTP1 ,XRCC1 gene sequence polymorphism.Results The number of patients with complete remission and partial remission and the num-ber of patients with stable and progress were not related to the gender,age,tumor location,pathological differentiation,TNM staging of patients (χ2=0.222~1.8,P>0.05).Of all cases,the frequencies of GSTP1A/A,A/G and G/G genotype were 68.3%,23.3% and 8.3%,respectively.GSTP1 gene wild-type (A/A)patients were treated with less efficiency than the GSTP1 gene mutation type (A/G+G/G)patients (χ2=4.493,P=0.034).Of all cases,the frequencies of XRCC1 G/G,G/A and A/A genotype were 58.3%,36.7% and 5%,respectively.XRCC1 gene wild type (G/G)patients with effective rate was higher than that of mutant type (G/A+A/A)patients (χ2=4.691,P=0.030).Conclusion The study showed that GSTP1(A/A),XRCC1 (G/G)gene polymorphism may be associated with clinical response to FOLFOX chemotherapy in advanced colorectal cancer.